


# PHARMACOKINETIC MONITORING OF SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

M. CHOVI TRULL<sup>1</sup>, M. GIL CANDEL<sup>1</sup>, M.R. MARQUÉS MIÑANA<sup>1</sup>, L. ESCOBAR HERNÁNDEZ<sup>1</sup>, N. FERRANDIS SALES<sup>1</sup>, B. ARNAU BLASCO<sup>1</sup>, M. RODENAS ROVIRA<sup>1</sup>, A. SOLANA ALTABELLA<sup>1</sup>, M. MARTIN CEREZUELA<sup>1</sup>, J. GARCIA PELLICER<sup>1</sup>, J.L. POVEDA ANDRÉS<sup>2</sup>


<sup>1</sup>Hospital Universitari i Politècnic La Fe, Pharmacy department, Valencia. <sup>2</sup> Hospital Universitari i Politècnic La Fe, Management department, Valencia.

\*corresponding author: mariach22ch@gmail.com

## BACKGROUND AND OBJECTIVES



- To analyze the **variability** of trough concentration (Cmin) of SC-IFX
- To establish a **cutoff** to achieve clinical response (CR), biochemical remission (RemBq) and clinical remission (RemC) during the maintenance phase in IBD patients.



## MATERIAL AND METHODS

### Study design

- Ambispective
- Observational
- Single center
- January 2020 - June 2024

- Data: electronic prescription program (**Abucasis**/MDIS program)

- Variables:

Demographic data	Diagnosis	Pharmacotherapeutic data	Biochemical parameters	Clinical score
<ul style="list-style-type: none"> <li>Sex</li> <li>Age</li> <li>Weight</li> </ul>	<ul style="list-style-type: none"> <li>Crohn disease (CD)</li> <li>Ulcerative colitis (UC)</li> </ul>	<ul style="list-style-type: none"> <li>Cmin (3rd, 6th, 12th months)</li> <li>Previous biological therapy</li> </ul>	<ul style="list-style-type: none"> <li>Albumin (ALB)</li> <li>Fecal calprotectin (FCP)</li> <li>C-reactive protein (CRP)</li> </ul>	<ul style="list-style-type: none"> <li>Partial-Mayo Score (MS): UC</li> <li>Harvey-Bradshaw (HB): CU</li> </ul>

• Results expression: percentage, and median [interquartile range(IQR)].

## RESULTS


	PATIENTS
n	52
IBD	CD (n=42)
	UC (n=10)
Age	45.0 [34.0 - 56.0]
Weight	70.0 [62.0-83.0]
Prior biologic treatment	n = 8

Table 1. Patient's characteristics.

CR	3rd	12th
Cmin (µg/mL)	13.5	13.7
AUC [95%CI] p_value	0.90 [0.82-0.98] p=0.024	0.77 [0.61-0.93] p= 0.020
S	0.83	0.68
E	0.87	0.88

Pharmacokinetic parameters (median [IQR])	3rd	6th	12th	p_value
Cmin (µg/mL)	15.1 [10.4-19.4]	13.7 [10.0-16.7]	14.3 [10.2-17.4]	0.226

Table 2. Pharmacokinetic parameters.



Biochemical parameters (median [IQR])	3rd	6th	12th
ALB (g/dL)	4.4 [4.2-4.6]	4.4 [4.2-4.5]	4.4 [4.3-4.7]
FCP (µg/g)	58.0 [30.5-199.4]	105.2 [37.4 -265.1]	75.6 [32.3-316.2]
CRP (mg/L)	1.3 [1.0-3.3]	1.5 [1.0-3.1]	1.4 [1.0-3.0]

Table 3. Biochemical parameters.

S: sensitivity, E: specificity

## CONCLUSIONS AND RELEVANCE

- SC-IFLX Cmin** remained stable over the follow-up period. A **cutoff** for **CR** was identified at **13.5 µg/mL** and **13.7 µg/mL**, and a cutoff of **16.8 µg/mL** for **RemBq**.
- Further studies are required to confirm these findings and establish an optimal cutoff that ensures favorable clinical outcomes.

